Chemical Nameafamelanotide
Dosage FormImplant (subcutaneous; 16 mg)
Drug ClassReceptor agonists
SystemBlood, Skin
Approval Year2019


  • Scenesse is indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP).
Last updated on 10/29/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Scenesse (afamelanotide) Prescribing Information 2019Clinuvel
Document TitleYearSource
Afamelanotide for erythropoietic protoporphyria. 2015New England Journal of Medicine